Haleon Pakistan Limited has achieved a significant milestone by exporting its first batch of locally manufactured Centrum multivitamins to Kenya. This marks an important step in the company’s expansion strategy, aiming to boost Pakistan’s pharmaceutical exports.
The shipment was produced at Haleon’s Jamshoro facility, reflecting the company’s commitment to enhancing local manufacturing capabilities and contributing to the national economy. The initiative aligns with Pakistan’s broader goal of increasing foreign exchange earnings by tapping into international markets.
According to Haleon Pakistan’s CEO, Farhan Muhammad Haroon, the company has been actively working towards strengthening its presence in the healthcare sector. “This export achievement is a testament to our efforts in making Pakistan a key player in the global nutraceutical industry,” he stated.
Haleon, formerly a part of GlaxoSmithKline (GSK), is a global leader in consumer healthcare. In addition to Centrum, the company has plans to expand its pain management portfolio, including Panadol products designed for menstrual pain and migraines.
The successful shipment to Kenya is expected to open doors for further trade opportunities, positioning Pakistan as a competitive player in the pharmaceutical and health supplement market. Haleon Pakistan aims to increase exports to contribute a significant share of its overall revenue in the coming years.
